EP0297946A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Cytochalasin purification methods and compositions
Assignee: Syracuse University
•
Filing: 1988-06-17
•
Granted: —
•
Expires: 2008-06-17
Abstract
Abstract The isolation and purification of cytochalasins from mold cultures, specifically purification of cytochalasins A and B from Drechslera dematioidea and of cytochalasin D from mold cultures of Zygosporium masonii is described. Cytochalasins may be used in in vivo chemotherapy of invasive and metastatic disease, and in combination chemotherapy against neoplasms. Vehicles such as liposomes, which afford sustained release of the cytochalasin, may be used in the administration of such compounds.
Inventors
- 👤 Thomas P. Fondy
- 👤 Peter Bousquet
- 👤 Karen J. Loucy
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 19:37
CPC Classifications
C; C07; C07D; C07D313/00; A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004; A61K31/33; A61K31/395; A61K31/40; A61K31/403; A61K31/4035; A61K9/00; A61K9/10; A61K9/127; A61P; A61P35/00
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
16 words
1 A pharmaceutical unit dosage form comprising a cytochalasin and a pharmaceutically acceptable carrier or diluent.
Claim 2
Dependent Claim
16 words
1 A pharmaceutical unit dosage form comprising a cytochalasin and a pharmaceutically acceptable carrier or diluent.
Claim 3
Dependent Claim
14 words
The pharmaceutical unit dosage form of claim 1 wherein the cytochalasin is cytochalasin B.
Claim 4
Dependent Claim
12 words
The pharmaceutical unit dosage form of claim 2 adapted for parenteral administration.
Claim 5
Dependent Claim
12 words
The pharmaceutical unit dosage form of claim 2 adapted for oral administration.
Claim 6
Dependent Claim
8 words
A composition comprising a cytochalasin and a liposome.
Claim 7
Dependent Claim
8 words
A composition comprising a cytochalasin and a liposome.
Claim 8
Dependent Claim
16 words
A pharmaceutical composition comprising the composition of claim 5 and a pharmaceutically acceptable carrier or diluent.
Claim 9
Dependent Claim
10 words
The composition of claim 5 additionally comprising an antineoplastic agent.
Claim 10
Dependent Claim
11 words
The composition of claim 7 wherein the antineoplastic agent is doxorubicin.
Claim 11
Dependent Claim
9 words
A composition comprising a cytochalasin and an antineoplastic agent.
Claim 12
Dependent Claim
9 words
A composition comprising a cytochalasin and an antineoplastic agent.
Claim 13
Dependent Claim
16 words
A pharmaceutical composition comprising the composition of claim 9 and a pharmaceutically acceptable carrier or diluent.
Claim 14
Dependent Claim
12 words
The pharmaceutical composition of claim 9 wherein the antineoplastic agent is doxorubicin.
Claim 15
Dependent Claim
12 words
The pharmaceutical composition of claim 11 wherein the cytochalasin is cytochalasin B.
Claim 16
Independent Claim
31 words
A method for inhibiting neoplastic cell growth in vitro comprising the step of administering synergistically-acting effective amounts of a synthetic or mold-derived membrane-acting compound and an antineoplastic agent to the cells.
Claim 17
Independent Claim
31 words
A method for inhibiting neoplastic cell growth in vitro comprising the step of administering synergistically-acting effective amounts of a synthetic or mold-derived membrane-acting compound and an antineoplastic agent to the cells.
Claim 18
Dependent Claim
15 words
The method of claim 13 wherein the synthetic or naturally-occurring membrane-acting compound is a cytochalasin.
Claim 19
Dependent Claim
11 words
The method of claim 14 wherein the cytochalasin is cytochalasin B.
Claim 20
Dependent Claim
11 words
The method of claim 15 wherein the antineoplastic agent is doxorubicin.
Claim 21
Dependent Claim
14 words
A synergistically-acting combination of a synthetic or mold-derived membrane-acting compound and an antineoplastic agent.
Claim 22
Dependent Claim
14 words
A synergistically-acting combination of a synthetic or mold-derived membrane-acting compound and an antineoplastic agent.
Claim 23
Dependent Claim
19 words
The synergistically-acting combination of claim 17 wherein the membrane-acting compound is a cytochalasin and the antineoplastic agent is doxorubicin.
Claim 24
Dependent Claim
17 words
A pharmaceutical composition comprising the synergistically-acting combination of claim 17 and a pharmaceutically acceptable carrier or diluent.
Claim 25
Dependent Claim
17 words
A composition comprising a mold-derived membrane-acting compound containing less than about 1% of other mold-derived membrane-acting compounds.
Claim 26
Dependent Claim
17 words
A composition comprising a mold-derived membrane-acting compound containing less than about 1% of other mold-derived membrane-acting compounds.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.